{
    "eid": "2-s2.0-85087466943",
    "title": "Recent developments in neoantigen-based cancer vaccines",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Bioinformatics",
        "Cancer",
        "Clinical trials",
        "Immunotherapy",
        "Vaccine"
    ],
    "authors": [
        "Kenneth Hodge",
        "Suangson Supabphol",
        "Pramod Kumar",
        "Witthaya Poomipak",
        "Trairak Pisitkun"
    ],
    "citedby-count": 5,
    "ref-count": 70,
    "ref-list": [
        "Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy",
        "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2",
        "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial",
        "Selection of regulatory T cells in the thymus",
        "T-cell tolerance: central and peripheral",
        "Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells",
        "Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade",
        "Genetic basis for clinical response to CTLA-4 blockade in melanoma",
        "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing",
        "Trafficking of T cells into tumors",
        "CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review",
        "Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia",
        "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples",
        "Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors",
        "Fast and robust deconvolution of tumor infiltrating lymphocyte from expression profiles using least trimmed squares",
        "Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma",
        "Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis",
        "A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients",
        "An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes",
        "The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis",
        "Immunogenic neoantigens derived from gene fusions stimulate T cell responses",
        "Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes",
        "Systematic Analysis of Splice-Site-Creating Mutations in Cancer",
        "Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients",
        "Intron retention is a source of neoepitopes in cancer",
        "Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration",
        "Noncoding regions are the main source of targetable tumor-specific antigens",
        "Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes",
        "Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma",
        "RNA editing in the forefront of epitranscriptomics and human health",
        "A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer",
        "Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry",
        "Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands",
        "Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia",
        "Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome",
        "Global Identification of Post-Translationally Spliced Peptides with Neo-Fusion",
        "A large fraction of HLA class I ligands are proteasome-generated spliced peptides",
        "Mapping the MHC Class I-Spliced Immunopeptidome of Cancer Cells",
        "Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens",
        "Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase",
        "Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing",
        "Exploiting the mutanome for tumor vaccination",
        "Mutant MHC class II epitopes drive therapeutic immune responses to cancer",
        "Combination therapy in combating cancer",
        "Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment",
        "Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety",
        "Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade",
        "Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial",
        "Designer vaccine nanodiscs for personalized cancer immunotherapy",
        "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer",
        "Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer",
        "The interplay of immunotherapy and chemotherapy: harnessing potential synergies",
        "Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy",
        "WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia",
        "Preclinical and clinical development of neoantigen vaccines",
        "Molecular and cellular mechanisms of DNA vaccines",
        "mRNA vaccines-a new era in vaccinology",
        "Advances in mRNA Vaccines for Infectious Diseases",
        "A Comparison of Plasmid DNA and mRNA as Vaccine Technologies",
        "Getting personal with neoantigen-based therapeutic cancer vaccines",
        "Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade",
        "Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma",
        "Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution",
        "Natural killer cell education in human health and disease",
        "Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry",
        "Second-and third-generation drugs for immuno-oncology treatment-The more the better?",
        "Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity",
        "Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity",
        "Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection",
        "Capturing the antigen landscape: HLA-E, CD1 and MR1"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn Academic Advancement",
        "Chulalongkorn University"
    ]
}